XNAS · Healthcare · Biotechnology
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-28 | Q1 2026 | 1.31 | 1.81 | +38.17% | $1.27B | ✅ Beat | -3.56% | -0.28% | -0.25% |
| 2026-02-10 | Q4 2025 | 1.83 | 1.80 | -1.64% | $1.51B | ❌ Miss | +0.62% | +1.11% | -8.02% |
| 2025-10-28 |
| Q3 2025 |
| 1.53 |
| 2.26 |
| +47.71% |
| $1.37B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-29 | Q2 2025 | 1.34 | 1.57 | +17.16% | $1.22B | ✅ Beat | — | — | — |
| 2025-04-29 | Q1 2025 | 1.03 | 1.16 | +12.62% | $1.05B | ✅ Beat | — | — | — |
| 2025-02-10 | Q4 2024 | 1.55 | 1.43 | -7.74% | $1.18B | ❌ Miss | — | — | — |
| 2024-10-29 | Q3 2024 | 1.09 | 1.07 | -1.83% | $1.14B | ❌ Miss | — | — | — |
| 2024-07-30 | Q2 2024 | -1.55 | -1.82 | -17.42% | $1.04B | ❌ Miss | — | — | — |
Showing last 8 quarters.